AstraZeneca analysis shows Arimidex superior to tamoxifen in sub-groups of breast cancer patients
Anglo-Swedish drug major AstraZeneca presented a new analysis of the ATAC trial of its Arimidex (anastrozole), showing that the drug was superior to tamoxifen in reducing the risk of breast cancer recurrence in postmenopausal women with hormone-receptor positive early breast cancer, at the International St Gallen Oncology Conference, held in Switzerland.
In ATAC, there were fewer recurrences in women with hormone-receptor positive breast cancer treated with anastrozole (n= 2,618) than tamoxifen (n=2,598) at two, five and nine years post-surgery (91 versus 133; 245 vs 312; 385 vs 488, respectively).
Arimidex 32% effective in AI treatment-responsive population
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze